ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Company profile
Ticker
ARDX
Exchange
Website
CEO
Michael Raab
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NTERYX INC
SEC CIK
ARDX stock data
Latest filings (excl ownership)
8-K
Other Events
23 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
2 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
5 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
Transcripts
ARDX
Earnings call transcript
2024 Q1
2 May 24
ARDX
Earnings call transcript
2023 Q4
22 Feb 24
ARDX
Earnings call transcript
2023 Q3
31 Oct 23
ARDX
Earnings call transcript
2023 Q2
2 Aug 23
ARDX
Earnings call transcript
2023 Q2
2 Aug 23
ARDX
Earnings call transcript
2023 Q1
4 May 23
ARDX
Earnings call transcript
2022 Q4
2 Mar 23
ARDX
Earnings call transcript
2022 Q3
6 Nov 22
ARDX
Earnings call transcript
2022 Q2
7 Aug 22
ARDX
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
4
Laura A Williams
23 May 24
4
David P. Rosenbaum
23 May 24
4
Susan Rodriguez
23 May 24
4
Justin A Renz
23 May 24
4
MICHAEL RAAB
23 May 24
4
ELIZABETH A GRAMMER
23 May 24
4
Robert Ora Felsch
23 May 24
4
Robert Blanks
23 May 24
4
MICHAEL RAAB
15 May 24
144
Notice of proposed sale of securities
14 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 36.15 mm | 36.15 mm | 36.15 mm | 36.15 mm | 36.15 mm | 36.15 mm |
Cash burn (monthly) | (no burn) | 4.70 mm | 8.80 mm | 5.38 mm | 11.91 mm | 6.72 mm |
Cash used (since last report) | n/a | 8.46 mm | 15.86 mm | 9.70 mm | 21.46 mm | 12.11 mm |
Cash remaining | n/a | 27.68 mm | 20.29 mm | 26.45 mm | 14.68 mm | 24.03 mm |
Runway (months of cash) | n/a | 5.9 | 2.3 | 4.9 | 1.2 | 3.6 |
Institutional ownership, Q1 2024
10.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 18 |
Closed positions | 80 |
Increased positions | 18 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 55.27 bn |
Total shares | 24.44 mm |
Total puts | 770.30 k |
Total calls | 589.50 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
New Enterprise Associates 12, Limited Partnership | 13.63 mm | $94.34 mm |
Flynn James E | 2.56 mm | $16.57 mm |
Susquehanna International | 1.64 mm | $11.95 bn |
BK Bank Of New York Mellon | 965.76 k | $7.05 bn |
BNP Paribas Arbitrage | 570.87 k | $4.17 bn |
Pekin Hardy Strauss | 542.66 k | $3.96 bn |
Russell Investments | 536.30 k | $3.91 bn |
TD Asset Management | 510.34 k | $3.73 bn |
Swiss National Bank | 458.30 k | $3.35 bn |
Hennion & Walsh Asset Management | 438.83 k | $3.20 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 May 24 | Robert Blanks | Common Stock | Sell | Dispose S | No | No | 7.811 | 4,855 | 37.92 k | 362,331 |
21 May 24 | Robert Ora Felsch | Common Stock | Sell | Dispose S | No | No | 7.811 | 3,485 | 27.22 k | 95,127 |
21 May 24 | Grammer Elizabeth A | Common Stock | Sell | Dispose S | No | No | 7.811 | 6,927 | 54.11 k | 199,469 |
21 May 24 | Michael Raab | Common Stock | Sell | Dispose S | No | No | 7.811 | 31,484 | 245.92 k | 1,277,773 |
21 May 24 | Renz Justin A | Common Stock | Sell | Dispose S | No | No | 7.811 | 5,167 | 40.36 k | 300,546 |
News
Piper Sandler Maintains Overweight on Ardelyx, Maintains $15 Price Target
24 May 24
What Analysts Are Saying About Ardelyx Stock
24 May 24
Wedbush Reiterates Outperform on Ardelyx, Maintains $15 Price Target
24 May 24
8 Health Care Stocks Whale Activity In Today's Session
23 May 24
Ardelyx Presents Additional Data On IBSRELA, A First-In-Class Treatment For IBS-C In Adults At The 2024 Digestive Disease Week Conference
21 May 24
Press releases
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
22 May 24
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
21 May 24
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
16 May 24
Ardelyx, Inc. Reports Employment Inducement Grants
14 May 24
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
7 May 24